JP7676358B2 - 免疫療法のための融合ポリペプチド - Google Patents

免疫療法のための融合ポリペプチド Download PDF

Info

Publication number
JP7676358B2
JP7676358B2 JP2022503794A JP2022503794A JP7676358B2 JP 7676358 B2 JP7676358 B2 JP 7676358B2 JP 2022503794 A JP2022503794 A JP 2022503794A JP 2022503794 A JP2022503794 A JP 2022503794A JP 7676358 B2 JP7676358 B2 JP 7676358B2
Authority
JP
Japan
Prior art keywords
certain embodiments
seq
amino acid
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022503794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543742A5 (https=
JP2022543742A (ja
Inventor
ミチェル サデライン，
アントン ドブリン，
モハマド ハミエ，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ
メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ, メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2022543742A publication Critical patent/JP2022543742A/ja
Publication of JP2022543742A5 publication Critical patent/JP2022543742A5/ja
Priority to JP2024198293A priority Critical patent/JP2025015619A/ja
Application granted granted Critical
Publication of JP7676358B2 publication Critical patent/JP7676358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
JP2022503794A 2019-07-19 2020-07-20 免疫療法のための融合ポリペプチド Active JP7676358B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024198293A JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962876338P 2019-07-19 2019-07-19
US62/876,338 2019-07-19
PCT/US2020/042753 WO2021016174A1 (en) 2019-07-19 2020-07-20 Fusion polypeptide for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024198293A Division JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2022543742A JP2022543742A (ja) 2022-10-14
JP2022543742A5 JP2022543742A5 (https=) 2023-07-28
JP7676358B2 true JP7676358B2 (ja) 2025-05-14

Family

ID=74192452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022503794A Active JP7676358B2 (ja) 2019-07-19 2020-07-20 免疫療法のための融合ポリペプチド
JP2024198293A Pending JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024198293A Pending JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Country Status (11)

Country Link
US (1) US20220133802A1 (https=)
EP (1) EP3999079A4 (https=)
JP (2) JP7676358B2 (https=)
KR (1) KR20220035471A (https=)
CN (1) CN115298208A (https=)
AU (1) AU2020315796A1 (https=)
BR (1) BR112022000976A2 (https=)
CA (1) CA3148072A1 (https=)
IL (1) IL289887A (https=)
MX (1) MX2022000769A (https=)
WO (1) WO2021016174A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277639A4 (en) * 2021-01-15 2025-03-05 Seattle Children's Hospital d/b/a Seattle Children's Research Institute HYBRID AND TRUNCATED IMMUNE CELL PROTEINS
IL305795A (en) * 2021-03-10 2023-11-01 B G Negev Technologies & Applications Ltd At Ben Gurion Univ Reporter cells expressing chimeric proteins for use in determining the presence and or activity of immune barrier molecules
US12486310B2 (en) 2021-04-21 2025-12-02 Brigham Young University Metastasis inhibiting protein
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023020471A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd123-targetting antibodies and uses thereof in cancer therapies
WO2023081542A1 (en) * 2021-11-02 2023-05-11 Christopher Mendoza Metastasis inhibiting protein
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
WO2023139269A1 (en) 2022-01-21 2023-07-27 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
JP2025536892A (ja) * 2022-10-21 2025-11-12 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ７０キメラ受容体を発現する細胞及びその用途
EP4605436A2 (en) * 2022-10-21 2025-08-27 Memorial Sloan-Kettering Cancer Center Cells and compositions for treating cancer
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2024227145A1 (en) * 2023-04-27 2024-10-31 Memorial Sloan-Kettering Cancer Center Enhanced fusion polypeptide for immunotherapy
WO2026078056A1 (en) * 2024-10-09 2026-04-16 Leibniz-Institut Für Immuntherapie (Lit) Engineered tnfr ligands

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506581A (ja) 2006-10-20 2010-03-04 メッドイミューン・リミテッド タンパク質変異体
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
JP2018508219A (ja) 2015-03-05 2018-03-29 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
JP2018518990A (ja) 2015-06-19 2018-07-19 セバスチャン コボルド Ｐｄ−１−ｃｄ２８融合タンパク質および医療におけるその使用
JP2018518974A (ja) 2015-06-25 2018-07-19 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
JP2019512251A (ja) 2016-03-23 2019-05-16 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） Ｐｄ−１及び４−１ｂｂの融合タンパク質

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
SI2856876T1 (en) * 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
PL3298033T5 (pl) * 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
CN106929523A (zh) * 2015-12-29 2017-07-07 中国人民解放军第二军医大学 酵母表达重组hCD80-GPI融合蛋白的制备及其在抗肿瘤中的应用
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
EP3231813A1 (en) * 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017181152A2 (en) * 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MX2018012472A (es) * 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
EP4628587A3 (en) 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
BR112019006781A2 (pt) * 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
CN108866003A (zh) * 2017-05-16 2018-11-23 科济生物医药（上海）有限公司 基因工程化的细胞及应用
CA3287539A1 (en) * 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
US12053490B2 (en) * 2017-10-26 2024-08-06 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
JP7416695B2 (ja) * 2017-12-29 2024-01-17 メモリアル スローン－ケタリング キャンサー センター 増強されたキメラ抗原受容体およびその使用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506581A (ja) 2006-10-20 2010-03-04 メッドイミューン・リミテッド タンパク質変異体
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
JP2018508219A (ja) 2015-03-05 2018-03-29 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
JP2018518990A (ja) 2015-06-19 2018-07-19 セバスチャン コボルド Ｐｄ−１−ｃｄ２８融合タンパク質および医療におけるその使用
JP2018518974A (ja) 2015-06-25 2018-07-19 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
JP2019512251A (ja) 2016-03-23 2019-05-16 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） Ｐｄ−１及び４−１ｂｂの融合タンパク質
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Also Published As

Publication number Publication date
JP2025015619A (ja) 2025-01-30
CA3148072A1 (en) 2021-01-28
MX2022000769A (es) 2022-05-18
WO2021016174A1 (en) 2021-01-28
BR112022000976A2 (pt) 2022-04-05
KR20220035471A (ko) 2022-03-22
JP2022543742A (ja) 2022-10-14
IL289887A (en) 2022-03-01
EP3999079A4 (en) 2024-04-03
US20220133802A1 (en) 2022-05-05
EP3999079A1 (en) 2022-05-25
CN115298208A (zh) 2022-11-04
AU2020315796A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7676358B2 (ja) 免疫療法のための融合ポリペプチド
KR102865130B1 (ko) 향상된 키메라 항원 수용체 및 그의 용도
JP2025172139A (ja) 非ｈｌａ制限ｔ細胞受容体およびその使用
JP7668261B2 (ja) 改良された免疫療法のための細胞およびその使用
CN111655270A (zh) 分泌il-36的免疫应答细胞及其用途
US20230051518A1 (en) Cells expressing c-kit mutations and uses thereof
JP7698655B2 (ja) Ｃｄ２８変異を有するキメラ抗原受容体およびその使用
CA3109630A1 (en) Leucine zipper-based compositions and methods of use
EP3710470A1 (en) Il-33 secreting immunoresponsive cells and uses thereof
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
US20260041715A1 (en) Enhanced fusion polypeptide for immunotherapy
BR122024009352A2 (pt) Receptor de antígeno quimérico (car), célula imunorresponsiva isolada e seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar uma neoplasia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250430

R150 Certificate of patent or registration of utility model

Ref document number: 7676358

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150